|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
653500440[E04260051]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/2ml/º´(2016.07.01)(ÇöÀç¾à°¡)
\606 ¿ø/2ml/º´(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¾×üÀÌ¸ç Æú¸®¿¡Æ¿·»À¸·Î µµ´Ï ´ÜÀ§À¯Ãâ¿ë±â¿¡ µé¾îÀÖ´Ù.
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
2¹Ð¸®¸®ÅÍ ¡¿10, 20, 50, 100¹ÙÀ̾Ë/ÆÑ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 2¹Ð¸®¸®ÅÍ |
20 ¹ÙÀÌ¾Ë |
8806535004405 |
8806535004429 |
ÀϹݡæÀü¹®(2013.3.1ºÎÅÍ) |
| 2¹Ð¸®¸®ÅÍ |
1 ¹ÙÀÌ¾Ë |
8806535004405 |
8806535004412 |
ÀϹݡæÀü¹®(2013.3.1ºÎÅÍ) |
|
| ÁÖ¼ººÐÄÚµå |
157902CLQ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806535004405 |
| º¸°ü¹æ¹ý |
¹ÐºÀ¿ë±â, 25µµ¾¾ ÀÌÇϺ¸°ü, Â÷±¤º¸Á¸ |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
È¿´ÉÈ¿´É.È¿°ú
±â°üÁöõ½Ä, °æ·Ã¼º,õ½Ä¼º±â°üÁö¿°, ¸¸¼º ±â°üÁö¿°, Æó±âÁ¾, ±ÔÆóÁõ, Æó°áÇÙ ¹× ±â°üÁö È®ÀåÁõµî õ½Ä¾ç È£Èí°ï¶õÁõÀ» ¼ö¹ÝÇÏ´Â Æó, ±â°üÁö Áúȯ, Ç×»ýÁ¦, °Å´ãÁ¦, ºÎ½ÅÇÇÁú È£¸£¸óÁ¦¿Í »ý¸®½Ä¿°¼ö ¿¡¾î·Î¼Ö ¿ä¹ýÀÇ Áغñ ¹× º¸Á¶Á¦
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¿ë¹ý¿ë¹ý.¿ë·®
- °£ÇæÀûÀÎ ¾ç¾Ðȯ±â ¿ä¹ý±â±â³ª Àû´çÇÑ ³×ºí¶óÀÌÀú¸¦ ÀÌ¿ëÇÏ¿© Åõ¿©ÇÑ´Ù.
- ±ÇÀå¿ë·®
. ¼ºÀÎ : ºê·Òȼö¼Ò»ê Æä³îÅ׷ѷμ 0.5-1.25¹Ð¸®±×¶÷À» 1ÀÏ 4ȸ Åõ¿©
. 6-14¼¼ : ºê·Òȼö¼Ò»ê Æä³îÅ׷ѷμ 0.5¹Ð¸®±×¶÷À» 1ÀÏ 4ȸ Åõ¿©
- °æ¿ì¿¡ µû¶ó 0.9% ¸ê±Õ»ý¸®½Ä¿°¼ö·Î Àû´çÈ÷ Èñ¼®ÇÏ¿© »ç¿ëÇÒ ¼ö ÀÖ´Ù.
|
| °æ°í |
ÀÌ ¾àÀ» Åõ¿©ÇÒ °æ¿ì¿¡´Â »ç¿ë¹ýÀ» Á¤È®È÷ ÀÌÇØÇÏ°í °úÀ×Åõ¿©ÇÏÁö ¾Êµµ·Ï ÇÑ´Ù. ¶ÇÇÑ ¼Ò¾Æ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀÌ ¹Ù¶÷Á÷Çϳª ¾î¿ ¼ö ¾øÀÌ »ç¿ëÇÒ °æ¿ì ´Ù¸¥ ÈíÀÔÁ¦°¡ ¹«È¿ÇÒ °æ¿ì¿¡ ÇÑÇÑ´Ù.
|
| ±Ý±â |
1) ±³°¨½Å°æ ÈïºÐ¼º ¾Æ¹Î·ù¿¡ °ú¹ÎÁõÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ
2) ºê·Òȼö¼Ò»êÆä³ëÅ×·ÑÁ¦Á¦³ª ÀÌ Á¦Ç°ÀÇ Ã·°¡Á¦ ¼ººÐ¿¡ °ú¹ÎÇÑ È¯ÀÚ
3) ºñÈļº Æó¼â¼º ½É±Ùº´ÁõȯÀÚ
4) ºÎÁ¤ºó¸Æ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
´ÙÀ½ÀÇ °æ¿ì¿¡´Â ȯÀÚ¿¡ ´ëÇÑ Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇØ¾ß ÇÏ¸ç Æ¯È÷ Ãßõ¿ë·®º¸´Ù °í¿ë·®À» ¾µ ¶§´Â ´õ¿í ±×·¯ÇÏ´Ù. : ÃæºÐÈ÷ Á¶ÀýµÇÁö ¾ÊÀº ´ç´¢º´, ÃÖ±Ù¿¡ ±Þ¼º½É±Ù°æ»öÀ» °æÇèÇÑ °æ¿ì, ½É°¢ÇÑ ½ÉÇ÷°ü°è Áúȯ(°íÇ÷¾Ð, ½ÉºÎÀüÁõ, ºÎÁ¤¸Æ ¶Ç´Â ¸»ÃÊÇ÷°üÀå¾Ö), °©»ó¼±±â´ÉÇ×Áø, Å©·Òģȼº¼¼Æ÷Á¾
|
| ÀÌ»ó¹ÝÀÀ |
1) Á¤½Å½Å°æ°è: ¶§¶§·Î µÎÅë, ¼öÁöÁøÀü, °ñ°Ý±ÙÀÇ ¹Ì¼¼ÇÑ ÁøÀü, Á¹À½, µå¹°°Ô ¾îÁö·¯¿ò, ½Å°æ°ú¹Î, ºÒ¸é, ½É¸®º¯È µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ¼Òȱâ°è: °¡²û ½Ä¿åºÎÁø, ¼ÒȺҷ®, ±¸¿ª, ±¸Åä µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼øÈ¯±â°è: ¶§¶§·Î ½É°èÇ×Áø, ºó¸Æ, Ç÷¾Ðº¯µ¿, µå¹°°Ô ºÎÁ¤¸Æ, ¼öÃà±âÇ÷¾ÐÁõ°¡, À̿ϱâÇ÷¾Ð°¨¼Ò µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ƯÈ÷ °í¿ë·®À» Åõ¿©ÇÒ ¶§ ±×·¯ÇÏ´Ù. ¥â2-ÀÚ±ØÁ¦ÀÇ »ç¿ëÀ¸·Î ½É°¢ÇÑ ÀúÄ®·ýÇ÷ÁõÀÌ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù.
4) È£Èí±â°è: µå¹°°Ô ±âħ, ±â°üÁö¿°, õ¸í, ¸Å¿ì µå¹°°Ô Àεο°, ºñÃæÇ÷ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) °ú¹ÎÁõ: ¸Å¿ì µå¹°°Ô ÇǺιßÁø, Ç÷°üºÎÁ¾, µÎµå·¯±â, ±â°üÁö°æ·Ã, ±¸°ÀεκÎÁ¾, ÀúÇ÷¾Ð, ÇãÅ» µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
6) ±âŸ: µå¹°°Ô ±¸°¥, ±¸³»¿°, ±Çۨ, ¹ßÇÑ, ±ÙÀ°¾àÈ¿Í ±ÙÀ°Åë, ±ÙÀ°°æ·ÃÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| ÀϹÝÀû ÁÖÀÇ |
1) °úµµÇÏ°Ô Åõ¿©¸¦ °è¼ÓÇÏ´Â °æ¿ì, ºÎÁ¤¸Æ ¶Ç´Â ½ÉÁ¤Áö¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ°í Æ¯È÷ ¹ßÀÛ¹ßÇö½ÃÀÇ ÈíÀÔÅõ¿©ÀÇ °æ¿ì¿¡´Â °ú·®Åõ¿©°¡ µÇ±â ½¬¿ì¹Ç·Î ÃæºÐÈ÷ ÁÖÀÇÇÑ´Ù.
2) ¿ë¹ý¿ë·® ¿¡ ¸Â°Ô »ç¿ëÇÏ¿©µµ È¿°ú°¡ ³ªÅ¸³ªÁö ¾Ê´Â °æ¿ì¿¡´Â ÀÌ ¾àÀÌ Àû´çÇÏÁö ¾ÊÀº °ÍÀ¸·Î »ý°¢Çϰí Åõ¿©¸¦ ÁßÁöÇÑ´Ù. ƯÈ÷ ¼Ò¾Æ¿¡ Åõ¿©½Ã¿¡´Â »ç¿ë¹ýÀ» Á¤È®È÷ ÁöµµÇÏ°í °æ°ú¸¦ ÃæºÐÈ÷ °üÂûÇÑ´Ù.
3) ¥â2-È¿´É¾à¿¡ ÀÇÇÑ ½ÉÇÑ Ç÷ûKÄ¡ÀÇ ÀúÇϰ¡ º¸°íµÇ¾î ÀÖ´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Ç÷û KÄ¡ÀÇ ÀúÇÏÀÛ¿ëÀº Å©»êƾ°è ¾à¹°, ½ºÅ×·ÎÀ̵åÁ¦ ¹× ÀÌ´¢Á¦ÀÇ º´¿ë¿¡ ÀÇÇÏ¿© ¾Ç鵃 ¼ö ÀÖÀ¸¹Ç·Î ÁßÁõ õ½Ä ȯÀÚÀÇ °æ¿ì¿¡´Â ƯÈ÷ ÁÖÀÇÇÑ´Ù. ´õ¿íÀÌ Àú»ê¼ÒÇ÷ÁõÀº Ç÷ûKÄ¡ÀÇ ÀúÇϰ¡ ½É¸®µë¿¡ ¹ÌÄ¡´Â ÀÛ¿ëÀ» Áõ°½Ãų ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Ç÷ûKÄ¡¸¦ ¸ð´ÏÅÍÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
4) ´Ù¸¥ ÈíÀÔ¿ë ¥â-È¿´É¾à°ú ¸¶Âù°¡Áö·Î ¿ÀÈ÷·Á ÀÌ ¾à¿¡ ÀÇÇØ Ä¡¸íÀûÀÎ ±â°üÁö °æ·ÃÀÌ ¹ß»ýµÉ ¼ö ÀÖ´Ù. ¸¸¾à ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª¸é Áï½Ã ÀÌ ¾àÀÇ Åõ¿©¸¦ ÁßÁöÇÏ°í ´Ù¸¥ Ä¡·á¹ýÀ¸·Î ´ëüÇÑ´Ù.
5) Àå±â»ç¿ë½Ã¿¡´Â ÇÊ¿äÇÒ ¶§¸¸(Áõ»óÀÌ ³ªÅ¸³¯ ¶§¸¸) »ç¿ëÇÏ´Â °ÍÀÌ ÁÁÀ¸¸ç, ȯÀÚ¿¡°Ô Àå±âÀûÀÎ ÆóÀÇ ¼Õ»óÀ» ¹æÁöÇÏ°í ±âµµÀÇ ¿°ÁõÀ» Ä¡·áÇϱâ À§ÇØ Ç׿°ÁõÁ¦(¿¹: ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÈíÀÔÁ¦)¸¦ Ãß°¡ÀûÀ¸·Î Åõ¿©Çϰųª Áõ·®ÇÏ´Â °ÍÀÌ °í·ÁµÈ´Ù.
6) ÀÌ ¾àÀ» ÇÁ·ÎÇÁ¶ó³î·Ñ µîÀÇ ºñ¼±ÅÃÀû ¥â-Â÷´ÜÁ¦¿Í º´¿ëÅõ¿©Çؼ´Â ¾ÈµÈ´Ù. ±×·¯³ª Ç×Äݸ°¼º ±â°üÁöÈ®ÀåÁ¦´Â µ¿½ÃÅõ¿©ÇÒ ¼ö ÀÖ´Ù.
7) È£Èí°ï¶õÀÌ ±Þ¼ºÀ¸·Î ºü¸£°Ô ½É鵃 °æ¿ì, Áï½Ã ÀÇ»ç¿Í »ó´ãÇØ¾ß ÇÑ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ÀÌ ¾àÀ» ¿¡Çdz×ÇÁ¸°, À̼ÒÇÁ·ÎÅ×·¹³î µîÀÇ Ä«Å×Äݾƹηù¿Í º´¿ëÇÏ¸é ºÎÁ¤¸Æ ¶Ç´Â ½ÉÁ¤Áö¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
2) MAOÀúÇØÁ¦³ª »ïȯ°è Ç׿ì¿ïÁ¦·Î Ä¡·áÁßÀΠȯÀÚ¿¡°Ô ÀÌ ¾àÀ» Åõ¿©Çϸé ÀÌ ¾àÀÇ Ç÷°ü°è¿¡ ´ëÇÑ ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖÀ¸¹Ç·Î ƯÈ÷ ÁÖÀÇÇÑ´Ù.
3) ÀÌ ¾àÀ» ÇÁ·ÎÇÁ¶ó³î·Ñ µîÀÇ ºñ¼±ÅÃÀû ¥â-Â÷´ÜÁ¦¿Í º´¿ëÅõ¿©ÇÏ¸é ±â°üÁöÈ®ÀåÀÛ¿ëÀÌ ½É°¢ÇÏ°Ô ÀúÇØµÉ ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
4) ´Ù·®ÀÇ ´Ù¸¥ ±³°¨½Å°æÈïºÐÁ¦¸¦ Åõ¿©¹Þ°íÀִ ȯÀÚ¿¡°Ô ÀÌ ¾àÀ» Åõ¿©½Ã¿¡´Â ÁÖÀÇÇÑ´Ù.
5) ¥â-È¿´É¾à, Ç×Äݸ°Á¦, Å©»êƾÀ¯µµÃ¼(¿¹: Å׿ÀÇʸ°)´Â Æä³ëÅ×·ÑÀÇ ÀÛ¿ëÀ» °È½Ãų ¼ö ÀÖ´Ù. ¥â-È¿´É¾à, Àü½ÅÀûÀ¸·Î Àû¿ëµÇ´Â Ç×Äݸ°Á¦, Å©»êƾÀ¯µµÃ¼(¿¹: Å׿ÀÇʸ°)¸¦ º´¿ëÅõ¿©ÇÏ´Â °ÍÀº ºÎÀÛ¿ëÀ» Áõ°¡½Ãų ¼öµµ ÀÖ´Ù.
6) ÇÒ·Îź, Æ®¸®Å¬·Î·Î¿¡Æ¿·», ÀÎÇ÷ç¶õ°ú °°Àº ÈíÀÔ¼º źȼö¼Ò ¸¶ÃëÁ¦´Â ¥â-È¿´É¾àÀÇ ½ÉÇ÷°ü°è¿¡ ´ëÇÑ ÀÛ¿ëÀ» °È½Ãų ¼ö ÀÖ´Ù.
|
| ÀӺο¡ ´ëÇÑ Åõ¿© |
[ÀӺαݱ⠼ººÐ Á¶È¸]
1)µ¿¹°½ÇÇè¿¡¼ ·§Æ®ÀÇ ÅÂÀÚ°ñ°ÝÀÌ»ó ÃâÇöºóµµÀÇ Áõ°¡°¡ º¸°íµÇ¾î ÀÖÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀӽŰ¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡°Ô´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù. 2)Æä³ëÅ×·ÑÀÇ ÀڱüöÃà ¾ïÁ¦È¿°ú¸¦ °í·ÁÇÏ¿©¾ß ÇÑ´Ù.
|
| ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© |
ÀüÀÓ»ó½ÃÇè °á°ú, Æä³ëÅ×·ÑÀÌ À¯ÁóÀ¸·Î ºÐºñµÇ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ¼öÀ¯½Ã ¾ÈÀü¼ºÀÌ È®¸³µÇÁö ¾Ê¾ÒÀ¸¹Ç·Î Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù.
|
| ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© |
<¼Ò¾Æ>
¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù.(ÇöÀç±îÁö´Â ÃæºÐÇÑ ÀÓ»ó¼ºÀûÀÌ ¾ø´Ù.)
|
| Àû¿ë»óÀÇ ÁÖÀÇ |
ÀÌ ¾àÀÇ Àå±â»ç¿ë¿¡ ´ëÇÑ ¿Ü±¹ ÀÓ»ó½ÃÇè °á°ú 100¥ìgÁ¤·®ÈíÀÔ(MDI) »ó¿ë½Ã À¯È¿¼ºÀÌ ÀÔÁõµÇ¾úÀ¸¹Ç·Î 200¥ìgÁ¤·®ÈíÀÔ(MDI)Àº 100¥ìgÁ¤·®ÈíÀÔ(MDI)»ç¿ëÀ¸·Î Ä¡·áµÇÁö ¾Ê´Â ȯÀÚ¿¡°Ô »ç¿ëÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇϹǷΠ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ ÈÄ »ç¿ëÇÑ´Ù.
|
| °ú·®Åõ¿© ¹× óġ |
1) ÁõÈÄ : °ú·®Åõ¿©½Ã ¥â-È¿´É¾àÀÇ ¾à¸®ÀÛ¿ë °È¿Í ºó¸Æ, ½É°èÇ×Áø, È«Á¶, ±¸¿ª, ºÒ¾È, ¾îÁö·¯¿ò, µÎÅë, ÁøÀü, °íÇ÷¾Ð, ÀúÇ÷¾Ð, ¸Æ¾ÐÀÇ Æø È®Àå, ÈäÅë, ºÎÁ¤¸Æ µî°ú °°Àº ºÎÀÛ¿ë ¹ßÇöÀÌ ¿¹»óµÈ´Ù.
2) Ä¡·á : ÀÌ ¾àÀÇ ¿¬¼ÓÅõ¿©Áß º¼ ¼ö ÀÖ´Â °ú·®Åõ¿©¿¡ ÀÇÇÑ Áõ»óÀº º¸Åë ÀÌ ¾àÀÇ Åõ¿©¸¦ ÁßÁöÇÏ¸é ¼Ò½ÇµÈ´Ù. ÀÌ ¾àÀÇ Àû´çÇÑ ÇØµ¶Á¦´Â ½ÉÀå¼±Åüº ¥â-Â÷´ÜÁ¦À̳ª ±â°üÁö Æó¼â¸¦ Áõ°¡½Ãų ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÀÖÀ¸¹Ç·Î õ½ÄȯÀÚ¿¡°Ô´Â ÁÖÀÇÇÏ¿© Åõ¿©ÇÏ¿©¾ß ÇÑ´Ù. ½É°¢ÇÑ °æ¿ì ÁøÁ¤Á¦, ½Å°æ¾ÈÁ¤Á¦¸¦ Åõ¿©ÇÑ´Ù.
|
ÀÓ»ó°Ë»çÄ¡¿¡ÀÇÇÑ ¿µÇâ |
ÀÌ ¾àÀº ¾Ë·¹¸£°Õ Çdz»¹ÝÀÀÀ» ¾ïÁ¦ÇϹǷΠ¾Ë·¹¸£°Õ Çdz»¹ÝÀÀ °Ë»ç¸¦ ½Ç½ÃÇϱâ Àü¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
¹ÐºÀ¿ë±â, 25µµ¾¾ ÀÌÇϺ¸°ü, Â÷±¤º¸Á¸ |
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
653500440[E04260051]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/2ml/º´(2016.07.01)(Ãֽžడ)
\606 ¿ø/2ml/º´(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¾×üÀÌ¸ç Æú¸®¿¡Æ¿·»À¸·Î µµ´Ï ´ÜÀ§À¯Ãâ¿ë±â¿¡ µé¾îÀÖ´Ù.
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
2¹Ð¸®¸®ÅÍ ¡¿10, 20, 50, 100¹ÙÀ̾Ë/ÆÑ |
| º¸°ü¹æ¹ý |
¹ÐºÀ¿ë±â, 25µµ¾¾ ÀÌÇϺ¸°ü, Â÷±¤º¸Á¸ |
µ¿ÀÏÁÖ¼ººÐÄÚµå °Ë»ö¼øÀ§ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Fenoterol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.
|
| Pharmacology |
Fenoterol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Fenoterol is a beta agonist designed to open up the airways to the lungs.
|
| Pharmacokinetics |
Fenoterol HBrÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : ÈíÀÔ ¶Ç´Â °æ±¸Åõ¿©½Ã ½Å¼ÓÇÏÁö¸¸ ºÒ¿ÏÀüÇÏ°Ô Èí¼öµÊ.
- ÃÖ°íÈ¿°ú ¹ßÇö½Ã°£
- °æ±¸ ÈíÀÔ : 10-15ºÐ
- °æ±¸ : 1-2 ½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 6½Ã°£
- ´ë»ç : ÃÊȸÅë°úÈ¿°ú Å. °£¿¡¼ ºñȰ¼ºÇü sulfate·Î ´ë»çµÊ.
- ¹Ý°¨±â : 6-7 ½Ã°£
- ¼Ò½Ç
- °æ±¸ Åõ¿©½Ã : ¾à 40%°¡ ´ëº¯À¸·Î ¹è¼³µÇ¸ç, 24½Ã°£ µ¿¾È¿¡´Â ¾à 35%°¡ ´ë»çü·Î, 2% ¹Ì¸¸ÀÌ ¹Ìº¯Èü·Î¼ ´¢¸¦ ÅëÇØ ¹è¼³µÊ.
|
| Biotransformation |
Fenoterol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic.
|
| Toxicity |
Fenoterol¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.
|
| Drug Interactions |
Fenoterol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acebutolol AntagonismAlseroxylon Increased arterial pressureAmitriptyline The tricyclic increases the sympathomimetic effectAmoxapine The tricyclic increases the sympathomimetic effectAtenolol AntagonismBetaxolol AntagonismBevantolol AntagonismBisoprolol AntagonismCarteolol AntagonismCarvedilol AntagonismClomipramine The tricyclic increases the sympathomimetic effectDesipramine The tricyclic increases the sympathomimetic effectDeserpidine Increased arterial pressureDoxepin The tricyclic increases the sympathomimetic effectEsmolol AntagonismImipramine The tricyclic increases the sympathomimetic effectIsocarboxazid Increased arterial pressureLabetalol AntagonismLinezolid Possible increase of arterial pressureMethyldopa Increased arterial pressureMetoprolol AntagonismMidodrine Increased arterial pressureMoclobemide Moclobemide increases the sympathomimetic effectNadolol AntagonismNortriptyline The tricyclic increases the sympathomimetic effectOxprenolol AntagonismPargyline Increased arterial pressureProtriptyline The tricyclic increases the sympathomimetic effectTrimipramine The tricyclic increases the sympathomimetic effectPenbutolol AntagonismPractolol AntagonismPhenelzine Increased arterial pressurePindolol AntagonismPropranolol AntagonismSotalol AntagonismTimolol AntagonismRasagiline Increased arterial pressureReserpine Increased arterial pressureTranylcypromine Increased arterial pressure
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Fenoterol¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.
|
| Drug Target |
[Drug Target]
|
| Description |
Fenoterol¿¡ ´ëÇÑ Description Á¤º¸ An adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. [PubChem]
|
| Drug Category |
Fenoterol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic beta-AgonistsBronchodilator AgentsSympathomimeticsTocolytic Agents
|
| Smiles String Canonical |
Fenoterol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1
|
| Smiles String Isomeric |
Fenoterol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H](CC1=CC=C(O)C=C1)NC[C@H](O)C1=CC(O)=CC(O)=C1
|
| InChI Identifier |
Fenoterol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
|
| Chemical IUPAC Name |
Fenoterol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-12-02
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|